Publications by authors named "J E Chaft"
Introduction: Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UTs) are a recently defined group of aggressive cancers in which the effectiveness of standard treatments for lung cancer is unknown.
Methods: We collected clinical, pathologic, and demographic variables from five institutions for patients whose tumors met criteria for SMARCA4-UTs (undifferentiated phenotype and loss of SMARCA4 (BRG1) by immunohistochemistry).
Results: We identified 92 patients with SMARCA4-UTs; 58 (63%) had stage IV disease at diagnosis and 16 (17%) developed recurrent or metastatic disease after initial diagnosis.
Objective: To identify clinicopathologic and genomic features associated with brain metastasis after resection of lung adenocarcinoma (LUAD) and to evaluate survival after brain metastasis.
Methods: Patients who underwent complete resection of stage I-IIIA LUAD between 2011 and 2020 were included. A subset of patients had broad-based panel next-generation sequencing performed on their tumors.
Background/purpose: The circadian clock governs the expression of genes related to immunity and DNA repair. We investigated whether the time of day of radiotherapy and/or systemic therapy infusions (chemotherapy or anti-PD-L1) are associated with disease control and survival in locally advanced non-small cell lung cancer (LA-NSCLC).
Materials/methods: 178 consecutive patients with inoperable LA-NSCLC who received definitive chemoradiotherapy followed by durvalumab between 5/2017-8/2022 were reviewed.
Article Synopsis
- Co-mutations of KRAS and STK11 genes in advanced non-small cell lung cancer (NSCLC) are linked to resistance against immune checkpoint blockade (ICB) therapies, although their impact in patients receiving neoadjuvant chemoimmunotherapy remains unclear.
- A study investigated how these gene mutations affect recurrence-free survival in resectable KRAS-mutated NSCLC, revealing that those with co-occurring STK11 mutations had a higher risk of recurrence compared to those without.
- Analysis of tumor-infiltrating T cells indicated that the presence of STK11 mutations altered T cell behavior, suggesting that certain T cell characteristics might hinder effective anti-tumor immune responses in patients with KRASmut/STK11